Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

305 results about "Serotonin" patented technology

Serotonin (/ˌsɛrəˈtoʊnɪn, ˌsɪərə-/) or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter. It has a popular image as a contributor to feelings of well-being and happiness, though its actual biological function is complex and multifaceted, modulating cognition, reward, learning, memory, and numerous physiological processes.

Bifidobacterium animalis subsp. Lactis, preparation and application of bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.
Owner:JILIN AGRICULTURAL UNIV

Lactobacillus reuteri CCFM1288 for relieving depressive mood and application of lactobacillus reuteri CCFM1288

PendingCN119331766AIncrease alpha-diversitymaintain steady stateMilk preparationNervous disorderSerotoninNervous system
The invention discloses lactobacillus reuteri CCFM1288 for relieving depressive mood and application of the lactobacillus reuteri CCFM1288, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1288 has the tryptophan metabolism capability, and can survive for 7 days in the intestinal tract; after the lactobacillus reuteri CCFM1288 intervenes a depressive mouse, anxiety-like and depression-like behaviors of the mouse can be obviously relieved, flora alpha-diversity is improved, intestinal symbiotic bacteria are promoted to secrete indole substances, intestinal homeostasis is maintained, hypothalamic-pituitary-adrenal axis hyperfunction is relieved, dopamine and serotonin neurotransmitter nervous system functions are improved, and the effect of preventing and treating depression is achieved. The neurotransmitter release is promoted, and the anti-depression effect is achieved. In clinical tests, intervention of Lactobacillus reuteri CCFM1288 can significantly improve the depressive symptom of MDD patients, and a new safe alleviation approach is provided for depression treatment.
Owner:JIANGNAN UNIV

Plasma metabolite composition for auxiliary diagnosis of subclinical mastitis of dairy cow and application of plasma metabolite composition

The invention relates to a plasma metabolite composition for auxiliary diagnosis of sub-clinical mastitis of dairy cows and application of the plasma metabolite composition. The plasma metabolite combination is a first combination and / or a second combination, and the first combination is composed of glyceryl monolinoleate, 2-methylthiophene, L-cystine, (S)-(+)-citramalic acid, 9-hydroxy-10, 12-octadecadienoic acid, 16-hydroxyhexadecanoic acid, tyrosine hydroxyproline, stearoyl serotonin and histamine; the first composition is composed of 4, 5-dimethyl-2, 4, 5-trimethyloxazole, 12, 13-epoxy octadecadienoic acid, 2-cyclotetradecene-1-ketone, 4 [alpha]-carboxyl-5 [alpha]-cholest-8-ene-3 [beta]-alcohol, N-arachidonyl dopamine d8, 9 (Z) and 11 (E)-conjugated linoleic acid, and the second composition is composed of 2, 5-dihydro-2, 4, 5-trimethyloxazole, 12, 13-epoxy octadecadienoic acid, 2-cyclotetradecene-1-ketone, 4 [alpha]-carboxyl-5 [alpha]-cholest-8-ene-3 [beta]-alcohol, N-arachidonyl dopamine A product prepared based on the plasma metabolite composition and used for auxiliary diagnosis of cow subclinical mastitis is simple in use method and high in accuracy, can be used for assisting a milk somatic cell number method to diagnose cow subclinical mastitis, and reduces the probability of false negative and false positive.
Owner:WUHAN ACADEMY OF AGRI SCI

Fermented lactobacillus mucilaginosus BM01 with bowel relaxing effect and application of fermented lactobacillus mucilaginosus BM01

PendingCN120290408ABacteriaDigestive systemDisease irritable bowelDisease
The invention belongs to the technical field of probiotics, and particularly relates to fermented lactobacillus mucus BM01 with an effect of relaxing bowel and application of the fermented lactobacillus mucus BM01. A new fermented lactobacillus mucus BM01 strain is separated from excrement of a healthy infant in Guangzhou city, Guangdong province, a zebra fish constipation model is constructed through loperamide hydrochloride, and research finds that the strain can remarkably promote intestinal tract movement, increase the content of in-vivo serotonin and inhibit the enzyme activity of dipeptidyl peptidase-4, so that the constipation of the zebra fish can be inhibited, the constipation of the zebra fish can be inhibited, and the constipation of the zebra fish can be inhibited. Therefore, the bowel relaxing effect is achieved. It is indicated that the BM01 strain can play the bowel relaxing effect through multiple mechanisms, has significant application value, can be used for research and development of drugs for treating constipation, irritable bowel syndrome and other intestinal diseases or development of health care products with the bowel relaxing effect, and can also be used as a feed additive to improve animal intestinal health and reduce disease risks. The culture benefit is improved.
Owner:GUANGZHOU HAILILAI FOOD CO LTD +1

Therapeutic phenethylamine compositions and methods of use

There are disclosed deuterated 2C—X phenethylamine compounds. the use of such compounds in the treatment of diseases associated with a serotonin 5-HIT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds. methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
Owner:CYBIN IRL LTD

Application of N-acetyl serotonin in preparation of medicine for treating type 2 diabetes

The invention discloses application of N-acetyl serotonin in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the field of biological medicine. In-vivo and in-vitro experiments prove that the N-acetyl serotonin can promote secretion of GLP-1, has the effects of obviously reducing blood sugar, being good in sugar tolerance and insulin tolerance, and is obviously improved aiming at high fasting blood glucose, high postprandial blood glucose, poor glucose tolerance and reduced insulin tolerance; the GLP-1 secretion insufficiency is obviously improved. The invention is of great significance in maintaining blood sugar stability and improving glucose and insulin tolerance of diabetic patients, and provides a new solution for treatment of type 2 diabetes mellitus.
Owner:THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIV MEDICAL COLLEGE +1

Application of N-acetyl serotonin in prevention and treatment of diabetes

ActiveCN119345192ASignificant improvementImproves glucose tolerance levelOrganic active ingredientsMetabolism disorderSerotoninBeta-cell Function
The invention relates to the technical field of biological medicines, in particular to application of N-acetyl serotonin in prevention and treatment of diabetes mellitus, and tests show that NAS has an obvious improvement effect on symptoms of weight loss, water intake increase and diet increase of T2DM mice; the NAS is used for improving the fasting blood glucose and the glucose tolerance level of the T2DM mouse; the NAS reduces the glycated serum protein and insulin resistance level of the T2DM mouse; the pancreatic beta cell function and insulin sensitivity of the T2DM mouse are improved. Therefore, the medicine N-acetyl serotonin has a good clinical application prospect in treating the type 2 diabetes mellitus and has important significance in developing a novel medicine composition for treating the type 2 diabetes mellitus.
Owner:GUANGXI MEDICAL UNIVERSITY

Application of grape acetyl serotonin O-methyltransferase gene VvAST in induction of seedless

The invention discloses an application of a grape acetyl serotonin O-methyltransferase gene VvAST in induction of seedless, and a preparation method of the grape acetyl serotonin O-methyltransferase gene. Nucleotide sequences and amino acid sequences and specific applications are provided. The invention shows that overexpression of VvAST in tomato can significantly inhibit seed development and generate seedless phenotypes. Therefore, the VvAST can be used as a key molecular target for regulating and controlling the development of grape and tomato seeds, and has potential application value. Through gene editing or regulation and control of the expression level, stable and efficient seedless grape breeding is expected to be realized, and industrial development of high-quality seedless grape fruits is promoted.
Owner:SHANDONG ACAD OF GRAPE

Therapeutic phenethylamine compositions and methods of use

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.
Owner:CYBIN IRL LTD

Mesenchymal stem cell culture medium without animal-derived components and application of mesenchymal stem cell culture medium

The invention relates to the technical field of cell culture. The invention provides a mesenchymal stem cell culture medium without animal-derived components and application of the mesenchymal stem cell culture medium. The culture medium comprises a basic culture medium and an additive, the additives comprise FGF-2, IGF-1, glutamine, folic acid, serotonin, cholesterol, arachidonic acid, an HEPES buffer solution, sodium bicarbonate, SCF, TGF-beta, PDGF, ascorbic acid and transferrin. The mesenchymal stem cell culture medium disclosed by the invention is completely free of animal-derived components, and meets the requirements of FDA / EMA clinical-grade cell therapy products. The culture medium can support high-density amplification of mesenchymal stem cells, the activity of passage cells is effectively improved, and the amplification time is shortened. The method has remarkable significance in improving the amplification efficiency of the mesenchymal stem cells and promoting and applying factory growth.
Owner:广东壹加再生医学研究院有限公司

Preparation method and application of electrochemical nano sensor for detecting serotonin

The invention provides a preparation method and application of an electrochemical nano sensor for detecting serotonin. The preparation method of the electrochemical nano sensor comprises the following steps: coupling dopamine on a carbon fiber nano electrode through cyclic voltammetry to obtain a CFNE / DA electrode; the CFNE / DA electrode is placed in a dsDNA solution for an electrochemical reaction, and a CFNE / DA / dsDNA electrode is obtained; the CFNE / DA / dsDNA electrode is placed in a methylene blue solution, methylene blue is embedded between double strands of dsDNA through the adsorption effect, and the CFNE / DA / MB / dsDNA electrochemical nano sensor is obtained. According to the invention, an aptamer apt of serotonin is introduced as a recognition element, so that the specific recognition capability of the sensor on a detected target is improved; the detection limit of the electrochemical nano sensor on serotonin is lower than 0.2 nM, and the detection range is 0.5 nM to 400 nM.
Owner:HUBEI UNIV

Preparation method and application of MoS2-Ti / Au modified PET film electrode molecularly imprinted electrochemical sensor

The invention provides a preparation method and application of a MoS2-Ti / Au modified PET (Polyethylene Terephthalate) film electrode molecularly imprinted electrochemical sensor. Comprising the following steps: step 1, preparing a MoS2-Ti / Au electrode material; step 2, preparing a Prussian blue solution; step 3, preparing a pyrrole solution; 4, preparing a molecular polymerization solution; 5, carrying out an electropolymerization reaction; and step 6, carrying out elution on the polymerized MIP electrode. The invention provides a preparation method and application of a MoS2-Ti / Au modified PET (Polyethylene Terephthalate) film electrode molecularly imprinted electrochemical sensor, the MoS2-Ti / Au modified electrode is used for preparing the molecularly imprinted electrochemical sensor and detecting serotonin, the MoS2-Ti / Au modified electrode has good reproducibility, acceptable stability and high selectivity, and the MoS2-Ti / Au modified electrode is used for preparing the molecularly imprinted electrochemical sensor and detecting serotonin. The target object can be detected more quickly, accurately and effectively.
Owner:RUIDIAN (GUANGDONG) BIOTECHNOLOGY CO LTD

Methods for evaluating antidepressant effects

The present invention aims to provide a method for evaluating the serotonin reuptake inhibitory effect of a composition containing valerian extract. [Solution] The present invention provides a method for evaluating antidepressant effects, which involves quantitatively analyzing one or more components contained in at least a part of a plant of the genus Valerian or a processed product thereof, and evaluating the antidepressant effect of the test substance by referring to the results of the quantitative analysis and criteria for antidepressant effect.
Owner:KUKI SANGYO CORP +2

Drug-loaded nano carbon dot for treating atherosclerosis and preparation method thereof

The invention discloses a drug-loaded nano carbon dot for treating atherosclerosis and a preparation method of the drug-loaded nano carbon dot, and belongs to the technical field of biological medicines. Malic acid, vitamin B1 and histamine phosphate are used as precursors, a one-step hydrothermal method is adopted to synthesize nitrogen-sulfur-phosphorus co-doped nano carbon dots NSP-CDs, a monascus extract and serotonin are loaded on the surfaces of the carbon dots through electrostatic adsorption, and the nano drug which is simple in structure and small in size and has a targeted therapy effect is prepared. The nano-drug has low cytotoxicity and good in-vivo biological safety, and can obviously reduce total cholesterol, triglyceride, low-density lipoprotein cholesterol and Hamp of a sick mouse; the results of E staining and oil red O staining show that the plaque condition of the atherosclerosis model mouse after treatment is obviously improved. The monascus extract loaded nano-drug provided by the invention can be used for treating atherosclerosis diseases, and is expected to become a novel drug for preventing and treating atherosclerosis.
Owner:SICHUAN UNIV

Noradrenergic and specific serotonergic anxiolytic and antidepressant, method for the production and use thereof

The present invention relates to a novel Noradrenergic and Specific Serotonergic Anxiolytic and Antidepressant (NaSSA) and a method for the production and use thereof for treating mental disorders.The subject of this invention is a novel noradrenergic and specific serotonergic drug for the treatment of mental disorders in humans, which is 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), a polymorphous modification thereof, and methods for the production and use thereof.
Owner:ALLA CHEM LLC +2

Aromatic heterocyclic derivatives having serotonin receptor binding activity

The present invention provides a compound which has a serotonin 5-HT2A receptor inverse agonist effect, a pharmaceutically acceptable salt thereof, and a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains the compound or the salt. Provided is a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I) (In formula (I), R1 is a substituted or unsubstituted aromatic heterocyclic group or the like, each R2 is independently a hydrogen atom or the like, each R3 is independently a hydrogen atom or the like, n is 1 or 2, R4 is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group, L is -NR8- or the like, R8 is a hydrogen atom or the like, each R5 is independently a hydrogen atom or the like, each R6 is independently a hydrogen atom or the like, p is 1 or 2, and R7 is a group represented by the other formula shown.) (In the other formula shown, R9 is substituted or unsubstituted alkyloxy or the like, R10 is a hydrogen atom or the like, R11 is halogen or the like, and m is 0 or 1.)
Owner:SHIONOGI & CO LTD

Composition for regulating production of interfering ribonucleic acid

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.
Owner:WYVERN PHARMACEUTICALS INC

Cyclic amine derivatives having serotonin receptor binding activity

Provided are a compound having serotonin 5-HT2A receptor antagonism and / or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and / or inverse agonism comprising them.A compound represented by Formula (I):wherein R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L1, L2) is (NH, N) or the like; R4 is a group represented by Formula:wherein p and q are each independently 2 or the like; Ra is substituted or unsubstituted alkyl or the like; Xb is each independently CRbRb′; Rb is each independently a hydrogen atom or the like; Rb′ is each independently a hydrogen atom or the like; Xc is each independently CRcRc′; Rc is each independently a hydrogen atom or the like; Rc′ is each independently a hydrogen atom or the like; Xd is CRd or the like; and Rd is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; and R7 is a group represented by Formula:wherein A is CR11 or the like; R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; and R11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.
Owner:SHIONOGI & CO LTD

Composition for regulating production of interfering ribonucleic acid

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.
Owner:WYVERN PHARMACEUTICALS INC

Neurotransmitter detection method based on a continuous reaction platform of integrated derivatization and solid phase extraction

The present invention discloses a neurotransmitter detection method based on an integrated derivatization and solid phase extraction continuous reaction platform; the neurotransmitters include at least: Class A neurotransmitters have no primary amine groups, hydroxyl groups, and carboxyl groups, and have secondary amine groups or quaternary ammonium groups; Class B neurotransmitters contain at least one of primary amine groups, hydroxyl groups, and carboxyl groups; before detection, an aqueous phase derivatization system containing benzoyl chloride is used to derivatize the neurotransmitters in the sample, and an aqueous formic acid solution is added to the obtained supernatant to mix and centrifuge, and the obtained supernatant is subjected to LC-MS analysis after solid phase extraction. The present invention forms an integrated derivatization and solid phase extraction continuous reaction platform through process design, and realizes high-sensitivity simultaneous detection of at least two types of neurotransmitters. Melatonin, serotonin, histamine, and dopamine are detected simultaneously with high sensitivity, and the detection sensitivity is 1pg / mL for melatonin, 1ng / mL for serotonin, 0.03ng / mL for histamine, and 10pg / mL for dopamine.
Owner:YUJING TECH SHANGHAI CO LTD

Nucleic acid for improving content of serotonin in tomatoes and use thereof

Provided is a mutated promoter sequence. The mutated promoter sequence has a base mutation relative to a parent promoter. The parent promoter is a promoter derived from a tomato SlTDC1 gene. The mutated promoter sequence results in an increase in the content of serotonin in tomato fruits, possessing broad application prospects.
Owner:SHANDONG SHUNFENG BIOTECH CO LTD

Microbe-based modulation of serotonin biosynthesis

PendingUS20250025520A1Unknown materialsSerotoninDisease
Methods and compositions that can be used to modulate serotonin level in a subject are disclosed herein. In some embodiments, the methods include adjusting the composition of gut microbiota in the subject. Also disclosed are methods of adjusting the level of one or more serotonin-related metabolites to modulate serotonin biosynthesis in a subject, and methods for treating serotonin-related diseases, for example disorders caused by serotonin deficiency.
Owner:RGT UNIV OF CALIFORNIA

Composition for regulating production of interfering ribonucleic acid

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.
Owner:WYVERN PHARMACEUTICALS INC